<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01506843</url>
  </required_header>
  <id_info>
    <org_study_id>F3046</org_study_id>
    <secondary_id>CNPq</secondary_id>
    <nct_id>NCT01506843</nct_id>
  </id_info>
  <brief_title>Sublingual Immunotherapy in Children With Allergic Rhinitis</brief_title>
  <acronym>SLIT</acronym>
  <official_title>Clinical Efficacy and Mucosal/Systemic Antibody Response Changes After Sublingual Immunotherapy in Mite-allergic Children in a Randomized Double-blind, Placebo-controlled Study in Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Uberlandia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Uberlandia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy and mucosal/systemic antibody
      response changes after SLIT using house dust mite allergen with or without bacterial extracts
      in mite-allergic children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with allergic rhinitis with or without asthma were selected for a randomized
      double-blind, placebo-controlled trial and distributed into three groups: DPT (Dpt allergen
      extract, n=34), DPT+MRB (Dpt allergen plus mixed respiratory bacterial extracts, n=36), and
      Placebo (n=32). Clinical evaluation and immunological analyses are being carried out before
      and after 12 and 18 months of treatment, including rhinitis/asthma symptom and medication
      scores, skin prick test (SPT) to Dpt, and measurements of Dpt-, Der p 1-, Der p 2-specific
      serum IgE, IgG4, IgG1 and -specific salivary IgA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Symptom and Medication Scores at 12 months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>For clinical evaluation will be used a questionnaire determining the symptom and medication scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Specific Antibody Levels.</measure>
    <time_frame>Baseline, 12 months and 18 Months</time_frame>
    <description>Measurement of serum specific antibodies (IgE, IgG1, IgG4, and IgA) to Dermatophagoides pteronyssinus total extract, and Der p 1 and Der p 2 allergens.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>mite allergen drop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children with allergic rhinitis sensitized with dust mites will receive progressive doses of allergen drops comparing those receiving placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mite plus bacterial extracts</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccine constituted with mite and bacterial extracts will be compared to placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be constituted by the same solution used to make dilution of the allergen extracts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mite, Mite and Bacterial or Placebo</intervention_name>
    <description>All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy</description>
    <arm_group_label>mite allergen drop</arm_group_label>
    <arm_group_label>mite plus bacterial extracts</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>mite allergen extract</other_name>
    <other_name>bacterial allergen extract</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of allergic rhinitis

          -  Positive skin test to Dermatophagoides pteronyssinus total extract

          -  Positive serum levels of specific IgE to D. pteronyssinus extract

        Exclusion Criteria:

          -  Previous allergen immunotherapy

          -  Use of antihistamines 1 week or topical corticosteroid up to 3 weeks prior to skin
             prick test

          -  Long term use of systemic corticosteroid.

          -  Airway infection 30 days prior to the selection.

          -  Children with severe asthma, malignant, cardiovascular or autoimmune diseases, under
             chemotherapy or immunosuppressor therapy.

          -  Users of cigarette smoke

          -  Presence of severe skin lesions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernesto A Taketomi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Uberlandia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma and Rhinitis Control Program</name>
      <address>
        <city>Itumbiara</city>
        <state>Goias</state>
        <zip>75503-520</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2012</study_first_posted>
  <last_update_submitted>January 9, 2012</last_update_submitted>
  <last_update_submitted_qc>January 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Uberlandia</investigator_affiliation>
    <investigator_full_name>Ernesto Akio Taketomi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>IgA antibody</keyword>
  <keyword>IgE antibody</keyword>
  <keyword>IgG1/IgG4 subclasses</keyword>
  <keyword>Mite allergy</keyword>
  <keyword>Sublingual immunotherapy</keyword>
  <keyword>Saliva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 9, 2012</submitted>
    <returned>February 8, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

